UniQure – Talk Bio

uniQure Secures FDA Agreement on Accelerated Approval Pathway for Huntington’s Disease Gene Therapy AMT-130

4 months ago talkbio0Tagged Accelerated, AMT-130, Approved, cUHDRS, gene therapy, Huntington 's disease, NEFL gene, NfL, Regenerative Medicine, RMAT, UniQure, United States Food and Drug Administration

uniQure, FDA, Accelerated Approval, Huntington’s Disease, Gene Therapy, AMT-130, cUHDRS, Neurofilament Light Chain (NfL), Regenerative Medicine Advanced Therapy (RMAT)

Biopharma Layoff Tracker 2024: uniQure, Vir, Arbutus, and More Cut Staff

9 months ago talkbio0Tagged Arbutus, Biopharma layoffs, Industry, UniQure, Vir

biopharma layoffs, uniQure, Vir, Arbutus, biotech industry, job cuts, restructuring initiatives

Biopharma Companies uniQure and Arbutus Announce Workforce Reductions to Focus on Priority Programs

9 months ago talkbio0Tagged Arbutus Biopharma, Biopharma, Clinical Trials, gene therapy, Priority, UniQure

uniQure, Arbutus Biopharma, layoffs, workforce reduction, biopharma, priority programs, gene therapy, clinical trials

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

10 months ago talkbio0Tagged AMT-130, cUHDRS, Disease Progression, gene therapy, Huntington 's disease, Huntington 's Disease Rating Scale, Identifier, neurofilament protein L, NfL, Phase I/II trials, Regenerative Medicine, RMAT, Unified - Type of Agreement, UniQure

uniQure, Huntington’s disease, AMT-130, gene therapy, Phase I/II trials, disease progression, neurofilament light protein (NfL), Unified Huntington’s Disease Rating Scale (cUHDRS), Regenerative Medicine Advanced Therapy (RMAT) designation

UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data

10 months ago talkbio0Tagged AMT-130, Clinical Trials, Composite, cUHDRS, Disease Progression, gene therapy, Huntington 's disease, Huntington 's Disease Rating Scale, Identifier, NEFL gene, Neurodegenerative Disorders, NfL, Phase, RMAT, Unified - Type of Agreement, UniQure, United States Food and Drug Administration

UniQure, Huntington’s disease, gene therapy, AMT-130, FDA, RMAT designation, Phase I/II clinical trials, neurodegenerative disorder, neurofilament light (NfL), disease progression, composite Unified Huntington’s Disease Rating Scale (cUHDRS).